Page 7 - FallNews2021

®
Tolmar, the global developer and worldwide manufacturer of ELIGARD ,
is establishing commercial operations in Canada and now has dedicated
®
local teams with expertise in uro-oncology to support ELIGARD in meeting
the needs of Canadian healthcare providers and patients.

Tolmar is a fully integrated specialty pharmaceutical company with a
®
strong track record of successful commercialization of ELIGARD either
through licensing partnerships or through Tolmar-owned commercialization
capabilities across 89 countries around the world.

CUA-Tolmar Community Urologist Continuing

Professional Development (CPD) Grant Program

Tolmar is proud to provide an unrestricted grant to the CUA-Tolmar
Community Continuing Professional Development (CPD) Grant Program,
for the first-ever matching grant, where Tolmar is providing $50,000

and the CUA is matching that amount, for a combined total investment
of $100,000. The grant is in line with CUA’s strategic plan, which will
support Community Urologists in scholarly initiatives that improve
urological care in Canada.

Any questions, please contact Tal Erdman

tal.erdman@cua.org 514-395-0376 ext. 43

© 2021 Tolmar Pharmaceuticals Canada, Inc. All rights reserved.
Tolmar Pharmaceuticals Canada, Inc. operates in Manitoba/Yukon as Tolmar Canada.
®
ELIGARD is a registered trademark of sanofi-aventis Canada Inc.
TPI.2021.2905.v1EN

7

TOL21-013_CUA Newsletter_EN_Final_R1.indd 1 2021-11-02 5:00 PM